The Stent of Choice in ACS patients The Stent of Choice in ACS 1) The Rationale…

Slides:

Advertisements

Similar presentations

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

Advertisements

Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,

Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.

3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.

Resolute all comers trial Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter,

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.

Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.

Dr. V.K.AJIT KUMAR PROFESSOR, DEPT. of CARDIOLOGY, SCTIMST, TRIVANDRUM STENT CHOICE IN AMI.

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

Clinical Result Overview

BIOSENSORS-CLINICAL UPDATE “LEADERS AND BEYOND” John E Shulze, CTO BIOSENSORS INTERNATIONAL GROUP Jan 29, 2010.

TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.

Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.

The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.

1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.

Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.

Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.

ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.

Compare Trial 2 year follow-up Peter Smits Maasstad Ziekenhuis Rotterdam The Netherlands.

WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.

Early and Late Stent Thrombosis Rates in 5,054 Real-World Patients from XIENCE V USA With and Without Dual Antiplatelet Therapy Interruptions James Hermiller,

NEXT A Prospective, Randomized Trial Comparing Cre8, a Polymer-Free Stent Eluting Sirolimus, to a Paclitaxel-Eluting Stent Didier Carrié, MD,PhD On behalf.

Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.

Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,

Two-year clinical outcomes in the EVOLVE FHU trial: A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian Meredith.

12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

For the HORIZONS-AMI Investigators

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

DES Should be Used as the Default Stent in ACS!

European and US Guidelines

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

SIRIUS Trial: Diameter Restenosis

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

What Has Been Tried and What Is True?

Primary endpoint at 1 year

American College of Cardiology Presented by Dr. Stephan Windecker

How and why this study may change my practice ?

BASKET-SAVAGE Trial design: Patients with a SVG lesion were randomized to a DES (Taxus Liberte; n = 89) versus a BMS (Liberte; n = 84). All patients were.

ENDEAVOR IV: 5 Year Final Outcomes

For the HORIZONS-AMI Investigators

For the HORIZONS-AMI Investigators

ISAR-SAFE Trial design: Patients with DES PCI received 6 months of open-label DAPT with aspirin and clopidogrel. At 6 months, they were randomized in a.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.

STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.

ENDEAVOR II Five-Year Clinical Follow-up

Translation Pathway for Coronary Stent Development- Clinical Endpoints

Gregg W. Stone, MD Columbia University Medical Center

ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS

Updated 3-Year Meta-Analysis of the TAXUS Clinical Trials Safety and Efficacy Demonstrated in 3,445 Randomized Patients Time allocation for this talk.

Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J

Long Term Clinical Results from the Endeavor Program: 5-Year Follow up

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant.

MACE: Death, MI or TLR at 5 years

Primary safety endpoint

The American College of Cardiology Presented by Dr. A. Abazid

Presentation transcript:

The Stent of Choice in ACS patients

The Stent of Choice in ACS 1) The Rationale…

1) The Rationale:  Titanium-Nitride-Oxide Coating Absolute Lowest Thrombogenicity Effective Restenosis Reduction Shortest DAP Therapy  Helicoidal Design Improved Trackability & Crossability The Stent of Choice in ACS

2) The Clinical Evidence… Titan2 vs. The Latest DES Generation

The BASE-ACS Randomized Trial BAS vs EES 12- Month Clinical Follow-Up TiTAN-2 XIENCE-V SOURCE: The BASE-ACS Randomized Controlled Trial Late Breaking Trial EuroPCR 2011

The BASE-ACS Randomized Trial  ACS Population  827 Patients  100% Patients Follow-Up SOURCE: The BASE-ACS Randomized Controlled Trial Late Breaking Trial EuroPCR 2011 Titan2 vs. The Latest DES Generation

The BASE-ACS RCT 12 months MACE: Cardiac Death, nonfatal MI or TLR 7.2% 2.6% 6.8% 3.9% TITAN-2 XIENCE-V % Months after Index Procedure % P non-inferiority = HR 0.94 ( )

TiTAN2 is Non-Inferior to XIENCE V at 12 months The BASE-ACS RCT MACE (%) P non-inferiority = TiTAN-2 XIENCE-V

The BASE-ACS Randomized Trial BAS vs EES 18- Month Clinical Follow-Up TiTAN-2 XIENCE-V SOURCE: The BASE-ACS Randomized Controlled Trial Late Breaking Trial ASIA PCR 2012

The BASE-ACS RCT MACE: Cardiac Death, nonfatal MI or TLR 7.2% 2.6% 6.8% 3.9% TITAN-2 XIENCE-V % % 18 months Months after Index Procedure

The BASE-ACS RCT 18 months MACE: Cardiac Death, nonfatal MI or TLR 7.2% 2.6% 6.8% 3.9% Days after Index Procedure TITAN-2 XIENCE-V % P = 0.74 HR 0.96 ( )

TiTAN2 vs. XIENCE V at 18 months The BASE-ACS RCT MACE (%) P = 0.74 P = 0.01 P = * Definite & Probable AMI (%) *Thrombosis (%) TiTAN-2 XIENCE-V TiTAN-2 XIENCE-V TiTAN-2 XIENCE-V

The BASE-ACS RCT Titan2 vs. The Latest DES Generation * Definite & Probable  At 12 months Titan-2 BAS demonstrates its Non-Inferiority vs. Xience-V EES in terms of MACE (9.6% vs 9.0%) in patients with ACS  At 18 months Titan2-BAS improves its MACE score vs. EES (10.8% vs. 11.7%) due to a significantly better safety profile in terms of hard clinical endpoints: AMI (2.6% vs. 6.3%, p=0.01) Thrombosis* (1.2% vs. 3.7%, p=0.021) (with significantly less DAPT duration: 8.7 vs.10.2 months, p<0.001)

The Evidence-Based Choice for Your ACS patients !

All cited trademarks are the property of their respective owners. This material is not intended for use in the United-States and certain other countries. Caution: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. ©2012 Hexacath or its affiliates.